Identification

Name
Losartan
Accession Number
DB00678  (APRD00052)
Type
Small Molecule
Groups
Approved
Description

Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.

Structure
Thumb
Synonyms
  • (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
  • 2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
  • DuP 89
  • Losartan
External IDs
HGP-1405 / HGP1405 / MK594
Product Ingredients
IngredientUNIICASInChI Key
Losartan Potassium3ST302B24A124750-99-8OXCMYAYHXIHQOA-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LosartanTablet50 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet100 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet25 mgOralActavis Pharma Company2012-01-25Not applicableCanada
CozaarTablet, film coated50 mg/1Oralbryant ranch prepack1995-04-142018-05-11Us
CozaarTablet, film coated50 mg/1OralMerck Sharp & Dohme Limited1995-04-14Not applicableUs0006 095220180810 16125 ho34bp
CozaarTablet25 mg/1OralRemedy Repack2011-04-072016-10-13Us
CozaarTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2004-06-02Not applicableUs
CozaarTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1995-04-14Not applicableUs00006 0960 54 nlmimage10 c31361ab
CozaarTablet, film coated25 mg/1OralRemedy Repack2011-05-192016-10-13Us
CozaarTablet25 mgOralMerck Ltd.1995-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ag-losartanTablet25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-losartanTablet50 mgOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartanTablet25 mgOralApotex Corporation2012-04-13Not applicableCanada
Apo-losartanTablet100 mgOralApotex Corporation2012-01-25Not applicableCanada
Auro-losartanTablet50.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet25.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet100.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Bio-losartanTablet25 mgOralBiomed Pharma2016-05-09Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Losartan/hctLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Act Losartan/hctLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Act Losartan/hctLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Ag-losartan HctzLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartan HctzLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-losartan/hctzLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartan/hctzLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartan/hctzLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Auro-losartan HctLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-losartan HctLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
International/Other Brands
Lortaan
Categories
UNII
JMS50MPO89
CAS number
114798-26-4
Weight
Average: 422.911
Monoisotopic: 422.162187095
Chemical Formula
C22H23ClN6O
InChI Key
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
IUPAC Name
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

Pharmacology

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Associated Conditions
Pharmacodynamics

Losartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of action

Losartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Losartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases.

Volume of distribution
  • 34 L [losartan, healthy subjects]
  • 12 L [active metabolite, healthy subjects]
Protein binding

99.7% protein bound, primarily to albumin

Metabolism

Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication.

Route of elimination

Following oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces.

Half life

The terminal t1/2 of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.

Clearance
  • Total plasma clearance = 600 mL/min Losartan
  • Total plasma clearance = 50 mL/min [active metabolite]
  • Renal clearance = 75 mL/min Losartan
  • Renal clearance = 25 mL/min [active metabolite]
Toxicity

Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Losartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Losartan.Experimental
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Losartan.Experimental, Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Losartan.Approved, Investigational
AbirateroneThe metabolism of Losartan can be decreased when combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Losartan.Approved, Investigational
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Acemetacin.Approved, Experimental, Investigational
AcetaminophenThe serum concentration of Losartan can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Losartan.Approved
AlbendazoleThe serum concentration of Losartan can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Losartan.Experimental, Investigational
AlectinibThe serum concentration of Losartan can be increased when it is combined with Alectinib.Approved, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Losartan.Approved, Investigational
AliskirenThe risk or severity of hyperkalemia can be increased when Aliskiren is combined with Losartan.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Losartan.Approved, Investigational
AlminoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Alminoprofen.Experimental
AlprenololLosartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Losartan.Approved, Investigational
AmifostineLosartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of hyperkalemia can be increased when Losartan is combined with Amiloride.Approved
AminophenazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Aminophenazone.Approved, Withdrawn
AmiodaroneThe serum concentration of Losartan can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Losartan.Approved
AmlodipineThe serum concentration of Losartan can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Losartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Losartan.Approved, Investigational
AmoxapineThe serum concentration of Losartan can be increased when it is combined with Amoxapine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Losartan.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Losartan.Approved, Investigational
AmsacrineThe serum concentration of Losartan can be increased when it is combined with Amsacrine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Losartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of hyperkalemia can be increased when Losartan is combined with Anisodamine.Investigational
AnnamycinThe serum concentration of Losartan can be increased when it is combined with Annamycin.Investigational
AntipyrineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Antipyrine.Approved, Investigational
AntrafenineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Losartan can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Losartan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Losartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Losartan is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Losartan can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe risk or severity of hyperkalemia can be increased when Ardeparin is combined with Losartan.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Losartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Losartan.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Losartan.Approved, Nutraceutical
AstemizoleThe serum concentration of Losartan can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Losartan.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Losartan can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Losartan.Approved
AtorvastatinThe serum concentration of Losartan can be increased when it is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Losartan.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Losartan.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Losartan.Approved, Investigational
AzapropazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Losartan can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe serum concentration of Losartan can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Losartan can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Losartan can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe metabolism of Balaglitazone can be decreased when combined with Losartan.Investigational
BalsalazideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Losartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Losartan.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Losartan.Approved, Investigational
BarnidipineLosartan may increase the antihypertensive activities of Barnidipine.Approved
BefunololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Losartan.Approved, Investigational
BemiparinThe risk or severity of hyperkalemia can be increased when Bemiparin is combined with Losartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Benazeprilat.Experimental
BendazacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Losartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Losartan.Withdrawn
BenorilateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Benoxaprofen.Withdrawn
BenzquinamideThe serum concentration of Losartan can be increased when it is combined with Benzquinamide.Withdrawn
BenzydamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Benzydamine.Approved
Benzyl alcoholThe serum concentration of Losartan can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Losartan can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Losartan.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Losartan.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Losartan.Approved
BevantololLosartan may increase the hypotensive activities of Bevantolol.Approved
BicalutamideThe serum concentration of Losartan can be increased when it is combined with Bicalutamide.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Losartan.Experimental
BimatoprostLosartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Biricodar dicitrateThe serum concentration of Losartan can be increased when it is combined with Biricodar dicitrate.Investigational
BisoprololBisoprolol may increase the hypotensive activities of Losartan.Approved
BoceprevirThe metabolism of Losartan can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Losartan.Approved, Investigational
BosentanThe serum concentration of Losartan can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Losartan.Approved
BQ-123Losartan may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe serum concentration of Losartan can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.Approved, Investigational
BretyliumLosartan may increase the hypotensive activities of Bretylium.Approved
BromfenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Losartan can be increased when it is combined with Bromocriptine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Losartan.Approved, Investigational
BucindololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Bucindolol.Investigational
BufexamacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Bufexamac.Approved, Experimental
BufuralolThe risk or severity of hyperkalemia can be increased when Losartan is combined with Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Losartan.Approved, Investigational
BupranololLosartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Losartan can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Losartan can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Losartan.Approved
CadralazineCadralazine may increase the hypotensive activities of Losartan.Experimental
CaffeineThe serum concentration of Losartan can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Losartan.Experimental
CanagliflozinThe risk or severity of hyperkalemia and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.Approved
CandesartanLosartan may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilLosartan may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Losartan.Experimental
CapecitabineThe metabolism of Losartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Captopril.Approved
CarbamazepineThe serum concentration of Losartan can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Losartan.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Losartan.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Losartan.Withdrawn
CarprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololLosartan may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Losartan can be increased when it is combined with Carvedilol.Approved, Investigational
CefoperazoneThe serum concentration of Losartan can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Losartan can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Losartan.Approved, Investigational
CeritinibThe serum concentration of Losartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Losartan.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Losartan.Approved, Investigational
CertoparinThe risk or severity of hyperkalemia can be increased when Certoparin is combined with Losartan.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Losartan.Approved
ChloroformThe serum concentration of Losartan can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
ChlorothiazideLosartan may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Losartan can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe serum concentration of Losartan can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Losartan.Approved
Choline magnesium trisalicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Choline magnesium trisalicylate.Approved
CicletanineLosartan may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe metabolism of Ciglitazone can be decreased when combined with Losartan.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Losartan.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Losartan.Approved, Investigational
CimicoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Cimicoxib.Investigational
CiprofloxacinThe risk or severity of hyperkalemia can be increased when Losartan is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Losartan.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Losartan.Approved
ClarithromycinThe metabolism of Losartan can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Losartan.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Losartan.Approved, Investigational
ClofazimineThe serum concentration of Losartan can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Losartan can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Losartan.Approved
ClonixinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Losartan.Approved
CloranololLosartan may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Losartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Losartan.Approved
CobicistatThe metabolism of Losartan can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Losartan.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Losartan.Approved
Concanamycin AThe serum concentration of Losartan can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Losartan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Losartan.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Losartan.Approved, Investigational
CrisaboroleThe metabolism of Losartan can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Losartan.Approved
CryptenamineLosartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe metabolism of Losartan can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideLosartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of hyperkalemia can be increased when Losartan is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Losartan.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Losartan.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Losartan.Approved
DabrafenibThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Losartan can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Losartan can be increased when it is combined with Dactinomycin.Approved, Investigational
DalteparinThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Losartan.Approved
DanaparoidThe risk or severity of hyperkalemia can be increased when Danaparoid is combined with Losartan.Approved, Withdrawn
DanazolThe metabolism of Losartan can be decreased when combined with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Losartan.Approved
DarunavirThe metabolism of Losartan can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Losartan.Approved
DaunorubicinThe serum concentration of Losartan can be increased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Losartan.Approved, Investigational
DeferasiroxThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Delapril.Investigational
DelavirdineThe metabolism of Losartan can be decreased when combined with Delavirdine.Approved
DeserpidineLosartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Losartan.Approved
DesipramineThe serum concentration of Losartan can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Losartan can be increased when it is combined with Desmethylsertraline.Experimental
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
DexibuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.Approved, Vet Approved
DexniguldipineThe serum concentration of Losartan can be increased when it is combined with Dexniguldipine.Experimental
DexverapamilThe serum concentration of Losartan can be increased when it is combined with Dexverapamil.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Losartan.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Losartan.Approved
DiclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenamide.Approved, Investigational
Diethyl etherThe serum concentration of Losartan can be increased when it is combined with Diethyl ether.Experimental
DiethylnorspermineLosartan may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Losartan.Approved, Investigational
DifenpiramideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Losartan.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Losartan.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Losartan.Approved, Investigational
DihydroergotamineThe serum concentration of Losartan can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Losartan can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Losartan.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Losartan.Approved, Investigational
DofequidarThe serum concentration of Losartan can be increased when it is combined with Dofequidar.Experimental, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Losartan.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
DorzolamideLosartan may increase the hypotensive activities of Dorzolamide.Approved
DovitinibThe serum concentration of Losartan can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Losartan can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Losartan.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Losartan.Approved, Investigational
DoxycyclineThe metabolism of Losartan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Losartan can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Losartan can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Losartan is combined with Drospirenone.Approved
DroxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Droxicam.Withdrawn
DuloxetineLosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe serum concentration of Losartan can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.Approved
EfavirenzThe serum concentration of Losartan can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineLosartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElacridarThe serum concentration of Losartan can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Losartan.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Losartan.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Losartan.Approved, Investigational
EmopamilThe serum concentration of Losartan can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat.Approved
EnalkirenThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Losartan.Experimental
EnasidenibThe serum concentration of Losartan can be increased when it is combined with Enasidenib.Approved, Investigational
EndralazineEndralazine may increase the hypotensive activities of Losartan.Experimental
EnoxaparinThe risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Losartan.Approved
EnzalutamideThe serum concentration of Losartan can be decreased when it is combined with Enzalutamide.Approved
EpanololLosartan may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Losartan.Approved, Investigational
EpirizoleThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Epirizole.Approved
EplerenoneThe risk or severity of hyperkalemia can be increased when Eplerenone is combined with Losartan.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Losartan.Approved
EprosartanLosartan may increase the hypotensive activities of Eprosartan.Approved
ErgonovineThe serum concentration of Losartan can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Losartan can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Losartan.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Losartan.Approved, Investigational
ErythromycinThe serum concentration of Losartan can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololLosartan may increase the hypotensive activities of Esatenolol.Experimental
EsmololLosartan may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe serum concentration of Losartan can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Losartan can be increased when it is combined with Estramustine.Approved, Investigational
EstriolThe serum concentration of Estriol can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Losartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.Approved, Investigational
EthenzamideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Losartan can be decreased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Losartan can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Losartan can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Losartan.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Losartan.Approved
FelbamateThe metabolism of Losartan can be decreased when combined with Felbamate.Approved
FelbinacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Felbinac.Experimental
FelodipineThe serum concentration of Losartan can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Fenbufen.Approved
FenofibrateThe serum concentration of Losartan can be increased when it is combined with Fenofibrate.Approved
FenoldopamLosartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Fenoprofen.Approved
FentanylThe serum concentration of Losartan can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Feprazone.Experimental
Ferulic acidLosartan may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Losartan.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Losartan.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Losartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Losartan.Approved, Investigational
FirocoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Firocoxib.Experimental, Vet Approved
FloctafenineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Losartan can be decreased when combined with Floxuridine.Approved
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Losartan.Approved
FluconazoleThe serum concentration of Losartan can be decreased when it is combined with Fluconazole.Approved, Investigational
FlunixinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Losartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Flupentixol can be increased when it is combined with Losartan.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Losartan can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Losartan can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Losartan.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Losartan.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Losartan.Approved
FluvoxamineThe serum concentration of Losartan can be increased when it is combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Forasartan.Experimental
FosamprenavirThe metabolism of Losartan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Losartan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinoprilat.Experimental
FosphenytoinThe metabolism of Losartan can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Losartan.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Losartan.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Losartan can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallopamilThe serum concentration of Losartan can be increased when it is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Losartan.Approved, Investigational
GemfibrozilThe metabolism of Losartan can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Losartan can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Losartan.Approved, Investigational
GlyburideThe serum concentration of Losartan can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Losartan can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Losartan.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Losartan.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Losartan.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Losartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Losartan.Approved
GuanazodineLosartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLosartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Losartan.Approved, Investigational
GuanoclorLosartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLosartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLosartan may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Losartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Losartan.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Heparin is combined with Losartan.Approved, Investigational
HexamethoniumLosartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Losartan.Approved
HM-30181The serum concentration of Losartan can be increased when it is combined with HM-30181.Experimental
HycanthoneThe serum concentration of Losartan can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Losartan.Experimental
HydralazineHydralazine may increase the hypotensive activities of Losartan.Approved
HydrochlorothiazideLosartan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Losartan.Approved, Vet Approved
HydroflumethiazideLosartan may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe serum concentration of Losartan can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Losartan.Approved
IbuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Losartan can be decreased when combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Losartan.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Losartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Losartan.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Losartan.Approved
IndapamideLosartan may increase the hypotensive activities of Indapamide.Approved
IndenololLosartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Losartan can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Losartan.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Losartan.Approved, Investigational
IproniazidIproniazid may increase the hypotensive activities of Losartan.Withdrawn
IrbesartanLosartan may increase the hypotensive activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Losartan.Approved, Investigational
IsavuconazoleThe serum concentration of Losartan can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Losartan can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Losartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Losartan.Approved, Vet Approved
IsoniazidThe metabolism of Losartan can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Losartan can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Losartan can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Losartan.Approved, Investigational
KebuzoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Losartan.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Losartan.Approved
KetoconazoleThe metabolism of Losartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Losartan.Approved
LacidipineLosartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Losartan.Approved, Investigational
LamotrigineThe serum concentration of Losartan can be decreased when it is combined with Lamotrigine.Approved, Investigational
LandiololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Landiolol.Investigational
LaniquidarThe serum concentration of Losartan can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Losartan can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Losartan can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Losartan.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Losartan.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Losartan.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Losartan.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Losartan.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Losartan.Approved, Investigational
LevobetaxololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Levobetaxolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Losartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Losartan.Approved, Investigational
LevodopaLosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Losartan.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Losartan.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Losartan.Approved, Investigational
LidocaineThe serum concentration of Losartan can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Losartan.Approved
LinezolidLinezolid may increase the hypotensive activities of Losartan.Approved, Investigational
LinsidomineLosartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.Approved, Investigational
Lithium cationThe serum concentration of Lithium cation can be increased when it is combined with Losartan.Experimental
LobeglitazoneThe metabolism of Lobeglitazone can be decreased when combined with Losartan.Approved, Investigational
LofexidineLosartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomerizineThe serum concentration of Losartan can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Losartan can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Losartan can be increased when it is combined with Lonafarnib.Investigational
LonazolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Losartan.Approved
LopinavirThe metabolism of Losartan can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Losartan can be increased when it is combined with Loratadine.Approved, Investigational
LornoxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Losartan can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe serum concentration of Losartan can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Losartan can be increased when it is combined with Loxapine.Approved
LoxoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Losartan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Losartan can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Losartan.Approved, Investigational
MacitentanLosartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Magnesium salicylate.Approved
ManidipineLosartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.Approved, Investigational
Mannitol busulfanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Mannitol busulfan.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Losartan.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Losartan.Approved, Investigational
Meclofenamic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Losartan can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Losartan can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MeloxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Losartan.Approved
MepindololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Mepindolol.Experimental
MesalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Metamizole.Approved, Investigational, Withdrawn
MethadoneThe serum concentration of Losartan can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Losartan.Approved
MethoserpidineLosartan may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Losartan.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.Approved
MethyldopaLosartan may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Losartan.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Losartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Losartan.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Losartan.Approved, Vet Approved
MetipranololLosartan may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Losartan.Approved
MetoprololMetoprolol may increase the hypotensive activities of Losartan.Approved, Investigational
MetronidazoleThe serum concentration of Losartan can be increased when it is combined with Metronidazole.Approved
MetyrosineLosartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe metabolism of Losartan can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Losartan can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Losartan can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Losartan can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Losartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Losartan.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Losartan.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Losartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Losartan.Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Losartan.Approved
MitotaneThe serum concentration of Losartan can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Losartan can be increased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Losartan.Approved, Investigational
ModafinilThe serum concentration of Losartan can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Losartan.Approved, Investigational
MonensinThe serum concentration of Losartan can be increased when it is combined with Monensin.Vet Approved
MorniflumateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Losartan.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Losartan.Approved, Investigational
MuzolimineLosartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Losartan.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Losartan.Approved, Investigational
NabumetoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Losartan.Approved
NadroparinThe risk or severity of hyperkalemia can be increased when Nadroparin is combined with Losartan.Approved, Investigational
NafcillinThe serum concentration of Losartan can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftopidilLosartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Losartan.Approved
NaloxoneThe metabolism of Losartan can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Naproxen.Approved, Vet Approved
NebivololLosartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Losartan can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Losartan can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Losartan.Approved, Vet Approved
NepafenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Nepafenac.Approved, Investigational
NeratinibThe serum concentration of Losartan can be increased when it is combined with Neratinib.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Losartan is combined with Nesiritide.Approved, Investigational
NetoglitazoneThe metabolism of Netoglitazone can be decreased when combined with Losartan.Experimental
NetupitantThe serum concentration of Losartan can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Losartan can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Losartan.Withdrawn
NicardipineThe metabolism of Losartan can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilThe risk or severity of hyperkalemia can be increased when Nicorandil is combined with Losartan.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Losartan.Approved
NifenazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Niflumic Acid.Approved
NigericinThe serum concentration of Losartan can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Losartan can be increased when it is combined with Niguldipine.Experimental
NilotinibThe metabolism of Losartan can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineLosartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Losartan can be increased when it is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Losartan.Approved
NisoldipineThe serum concentration of Losartan can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Losartan can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Losartan.Approved
NitroaspirinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Losartan.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Losartan.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Losartan.Approved
NS-398The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with NS-398.Experimental
ObinutuzumabLosartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Losartan.Withdrawn
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Losartan.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Losartan.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Losartan.Approved, Investigational
OlaparibThe metabolism of Losartan can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Losartan.Approved, Investigational
OlsalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Losartan is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Losartan.Approved, Investigational
OmeprazoleThe serum concentration of Losartan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Losartan.Approved
ONT-093The serum concentration of Losartan can be increased when it is combined with ONT-093.Investigational
OxaprozinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Oxaprozin.Approved
OxcarbazepineThe serum concentration of Losartan can be decreased when it is combined with Oxcarbazepine.Approved
OxprenololLosartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe serum concentration of Losartan can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Losartan can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Losartan.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Losartan.Approved, Investigational
PantoprazoleThe serum concentration of Losartan can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Losartan.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Losartan.Approved, Investigational
ParnaparinThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Losartan.Approved, Investigational
ParoxetineThe serum concentration of Losartan can be increased when it is combined with Paroxetine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Losartan can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Losartan.Approved
PenbutololLosartan may increase the hypotensive activities of Penbutolol.Approved, Investigational
Penicillin G Acyl-SerineThe risk or severity of hyperkalemia can be increased when Losartan is combined with Penicillin G Acyl-Serine.Experimental
PentamidineThe risk or severity of hyperkalemia can be increased when Losartan is combined with Pentamidine.Approved, Investigational
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Losartan.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Losartan.Approved, Investigational, Vet Approved
PentoliniumLosartan may increase the hypotensive activities of Pentolinium.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Perindopril.Approved
PerindoprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Perindoprilat.Experimental
PethidineThe serum concentration of Losartan can be increased when it is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Losartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Losartan.Withdrawn
PhenobarbitalThe serum concentration of Losartan can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Losartan.Vet Approved
PhenoxybenzamineLosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Losartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Losartan.Approved, Investigational
PhentolamineLosartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Losartan can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Losartan.Approved, Investigational
PimozideThe serum concentration of Losartan can be increased when it is combined with Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Losartan.Approved
PindololLosartan may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Losartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Losartan.Approved, Investigational
PiperineThe metabolism of Losartan can be decreased when combined with Piperine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Losartan.Approved
PiroxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Losartan.Approved
PitolisantThe serum concentration of Losartan can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Losartan.Withdrawn
PolythiazideLosartan may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Losartan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Losartan.Approved, Investigational
PosaconazoleThe metabolism of Losartan can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Losartan.Approved, Investigational
Potassium bicarbonateThe risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Losartan.Approved
Potassium cationThe risk or severity of hyperkalemia can be increased when Potassium cation is combined with Losartan.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Losartan.Approved, Withdrawn
Potassium CitrateThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Losartan.Approved, Investigational, Vet Approved
PractololLosartan may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Losartan.Approved, Investigational
PranoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Pranoprofen.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Losartan.Approved
PrazosinThe serum concentration of Losartan can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Losartan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Losartan.Approved, Vet Approved
PrimaquineThe serum concentration of Losartan can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Losartan can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Losartan can be increased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Proglumetacin.Experimental
PromethazineThe serum concentration of Losartan can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Propacetamol.Approved, Investigational
PropafenoneThe serum concentration of Losartan can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Losartan can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Losartan.Approved, Investigational
PropyphenazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Losartan can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Losartan.Approved
QuercetinThe serum concentration of Losartan can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Losartan.Approved
QuinacrineThe serum concentration of Losartan can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Quinaprilat.Experimental
QuinidineThe serum concentration of Losartan can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Losartan can be increased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Ramipril.Approved
RamiprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Ramiprilat.Experimental
RanitidineThe serum concentration of Losartan can be increased when it is combined with Ranitidine.Approved
RasagilineRasagiline may increase the hypotensive activities of Losartan.Approved
ReboxetineThe serum concentration of Losartan can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Losartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Losartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Losartan.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Losartan.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Losartan can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Losartan can be increased when it is combined with Reversin 121.Experimental
ReviparinThe risk or severity of hyperkalemia can be increased when Reviparin is combined with Losartan.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Losartan.Experimental
RifamycinThe metabolism of Losartan can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Losartan can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Losartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Losartan.Approved, Investigational
RilpivirineThe serum concentration of Losartan can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe metabolism of Losartan can be increased when combined with Rimexolone.Approved
RiociguatLosartan may increase the hypotensive activities of Riociguat.Approved
RisperidoneLosartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Losartan can be decreased when it is combined with Ritonavir.Approved, Investigational
RituximabLosartan may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Losartan.Approved
RivoglitazoneThe metabolism of Rivoglitazone can be decreased when combined with Losartan.Experimental, Investigational
RobenacoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Rofecoxib.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Losartan can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Losartan.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Losartan.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Losartan.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Losartan.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Losartan.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Losartan.Approved
SafinamideSafinamide may increase the hypotensive activities of Losartan.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Losartan.Withdrawn
SalicylamideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Losartan can be increased when it is combined with Salinomycin.Vet Approved
SalsalateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Salsalate.Approved
SaprisartanLosartan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Losartan can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of hyperkalemia can be increased when Saralasin is combined with Losartan.Investigational
SarilumabThe therapeutic efficacy of Losartan can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Losartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Losartan.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Losartan.Approved
SertralineThe serum concentration of Losartan can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Losartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Losartan.Approved
SiltuximabThe serum concentration of Losartan can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Losartan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Losartan.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Losartan.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Losartan.Approved, Investigational
SitaxentanLosartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe risk or severity of nephrotoxicity can be increased when Losartan is combined with Sodium phosphate, monobasic.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Losartan.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Losartan.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Losartan.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Losartan.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Losartan.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Losartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Losartan is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Losartan can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Losartan.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Losartan.Experimental
StaurosporineThe serum concentration of Losartan can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Losartan can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Losartan.Approved, Investigational
SuccinylcholineThe risk or severity of hyperkalemia can be increased when Losartan is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Losartan.Approved, Investigational
SulfasalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Sulindac.Approved, Investigational
SulodexideThe risk or severity of hyperkalemia can be increased when Sulodexide is combined with Losartan.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Losartan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Losartan.Approved, Investigational
SuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Suprofen.Approved, Withdrawn
SuvorexantThe serum concentration of Losartan can be increased when it is combined with Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Losartan.Investigational, Withdrawn
TacrolimusThe serum concentration of Losartan can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Losartan.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Losartan.Investigational
TalniflumateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Talniflumate.Approved
TamoxifenThe serum concentration of Losartan can be increased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Losartan.Approved, Investigational
TariquidarThe serum concentration of Losartan can be increased when it is combined with Tariquidar.Investigational
TasosartanThe risk or severity of hyperkalemia can be increased when Tasosartan is combined with Losartan.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Losartan.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Losartan.Approved, Investigational
TelaprevirThe metabolism of Losartan can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Losartan can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Losartan can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.Approved
TenidapThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Losartan.Approved
TenoxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tepoxalin.Vet Approved
TerazosinLosartan may increase the hypotensive activities of Terazosin.Approved
TerfenadineThe serum concentration of Losartan can be increased when it is combined with Terfenadine.Approved, Withdrawn
TertatololThe risk or severity of hyperkalemia can be increased when Losartan is combined with Tertatolol.Experimental
TesmilifeneThe serum concentration of Losartan can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Losartan can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Losartan can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Losartan can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Losartan can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Losartan can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Losartan.Approved, Vet Approved
TetrahydropalmatineLosartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetrandrineThe serum concentration of Losartan can be increased when it is combined with Tetrandrine.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Losartan.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Losartan.Approved
ThiamylalThiamylal may increase the hypotensive activities of Losartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Losartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Losartan.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Losartan.Approved
TicrynafenLosartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Losartan.Approved
TinoridineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Losartan.Approved
TipifarnibThe serum concentration of Losartan can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Losartan can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Losartan is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneLosartan may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineLosartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Losartan.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tolmetin.Approved
TolonidineLosartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Losartan.Approved
TolvaptanThe risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Losartan.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Losartan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Losartan.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Losartan.Approved
ToremifeneThe serum concentration of Losartan can be increased when it is combined with Toremifene.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Losartan.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Losartan.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Losartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Losartan.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Losartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of hyperkalemia can be increased when Losartan is combined with Triamterene.Approved
TrichlormethiazideLosartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Losartan can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Losartan can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Losartan.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Losartan.Approved, Investigational
TrimethoprimThe risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Losartan.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Losartan.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Losartan.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Losartan can be decreased when combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Losartan.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Losartan.Approved
UnoprostoneLosartan may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Losartan.Investigational
ValdecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Losartan.Experimental
Valproic AcidThe metabolism of Losartan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Losartan.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Losartan.Investigational
VardenafilVardenafil may increase the antihypertensive activities of Losartan.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Losartan.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Losartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Losartan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Losartan.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Losartan.Approved
VerapamilThe serum concentration of Losartan can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Losartan.Approved
VincamineLosartan may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Losartan.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Losartan.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Losartan.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Losartan.Approved, Investigational
VoacamineThe serum concentration of Losartan can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Losartan can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Losartan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Losartan.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Losartan.Approved, Investigational
VTP-27999The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Losartan.Investigational
XipamideLosartan may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Losartan.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Losartan can be decreased when it is combined with Zidovudine.Approved
ZiprasidoneThe metabolism of Losartan can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Losartan can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
  • Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.

References

Synthesis Reference

Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan, "Polymorphs of losartan and the process for the preparation of form II of losartan." U.S. Patent US5608075, issued May, 1994.

US5608075
General References
  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178]
  2. Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325]
  3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194]
  4. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  5. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660]
  6. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328]
External Links
Human Metabolome Database
HMDB0014816
KEGG Drug
D08146
KEGG Compound
C07072
PubChem Compound
3961
PubChem Substance
46506538
ChemSpider
3824
BindingDB
82258
ChEBI
6541
ChEMBL
CHEMBL191
Therapeutic Targets Database
DAP000523
PharmGKB
PA450268
IUPHAR
590
Guide to Pharmacology
GtP Drug Page
HET
LSN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Losartan
ATC Codes
C09DA01 — Losartan and diureticsC09DB06 — Losartan and amlodipineC09CA01 — Losartan
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
PDB Entries
5x23 / 5x24 / 5xxi
FDA label
Download (212 KB)
MSDS
Download (19 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
0CompletedBasic SciencePeripheral Arterial Disease (PAD)1
0CompletedDiagnosticPostural Tachycardia Syndrome1
0CompletedTreatmentDiabetic Nephropathies1
0CompletedTreatmentSickle Cell Disorders1
0Not Yet RecruitingOtherCystic Fibrosis (CF)1
0Not Yet RecruitingTreatmentBlood Pressures / High Blood Pressure (Hypertension)1
1CompletedNot AvailableHealthy Volunteers11
1CompletedNot AvailableKidney Diseases1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHypertension(HTN)1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticHigh Blood Pressure (Hypertension)1
1CompletedHealth Services ResearchHealthy Volunteers2
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentCardiovascular Disease (CVD)1
1CompletedTreatmentFasting1
1CompletedTreatmentHigh Blood Pressure (Hypertension)4
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
1TerminatedBasic ScienceHigh Blood Pressure (Hypertension) / Multiple System Atrophy (MSA) / Progressive autonomic failure1
1Unknown StatusTreatmentHealthy Volunteers1
1, 2CompletedTreatmentAging1
1, 2RecruitingTreatmentChildren / Pulmonary vein stenosis1
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2RecruitingTreatmentHamstring Injury1
1, 2TerminatedTreatmentAlbinism, Oculocutaneous / Hermansky-Pudlak Syndrome (HPS) / Metabolic Diseases / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2Active Not RecruitingPreventionHigh Blood Pressure (Hypertension) / Hyperlipidemias1
2Active Not RecruitingTreatmentConnective Tissue Disorders / Oesophagitis, Eosinophilic1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionInflammatory Reaction1
2CompletedPreventionSarcopenia1
2CompletedTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension) / Hyperkalemia1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHigh Blood Pressure (Hypertension)1
2CompletedTreatmentHigh Blood Pressure (Hypertension) / Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour)1
2CompletedTreatmentHypertrophic Cardiomyopathy2
2CompletedTreatmentMarfan Syndrome1
2CompletedTreatmentNAFLD1
2CompletedTreatmentRenal Dysfunction / Sickle Cell Disorders1
2CompletedTreatmentTransplant, Kidney1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Pancreas1
2Not Yet RecruitingTreatmentNAFLD - Nonalcoholic Fatty Liver Disease1
2RecruitingPreventionAging / High Blood Pressure (Hypertension) / Sedentary Lifestyle1
2RecruitingPreventionStress Disorders, Post-Traumatic1
2RecruitingTreatmentCystic Fibrosis (CF)1
2RecruitingTreatmentHeart Defects,Congenital / Tetralogy Of Fallot / Ventricular Dysfunction, Right1
2RecruitingTreatmentHigh Blood Pressure (Hypertension)2
2RecruitingTreatmentHigh Blood Pressure (Hypertension) / Kidney Diseases / Proteinuria / Sickle Cell Disorders1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingTreatmentOesophagitis, Eosinophilic1
2TerminatedTreatmentHigh Blood Pressure (Hypertension)1
2TerminatedTreatmentHigh Blood Pressure (Hypertension) / Unspecified Adult Solid Tumor, Protocol Specific1
2TerminatedTreatmentPre-Diabetic / Pre-Hypertension1
2Unknown StatusPreventionMarfan Syndrome1
2Unknown StatusTreatmentHypertension,Essential1
2Unknown StatusTreatmentNonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis1
2, 3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / High Blood Pressure (Hypertension) / Subjective Cognitive Decline1
2, 3TerminatedTreatmentDiabetic Nephropathies1
2, 3WithdrawnTreatmentHigh Blood Pressure (Hypertension)1
3Active Not RecruitingTreatmentNewly-diagnosed Glioblastoma1
3CompletedPreventionLung Cancers / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentArterial Hypertension1
3CompletedTreatmentBMI >27 kg/m2 / High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
3CompletedTreatmentCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
3CompletedTreatmentDiabetic Nephropathies1
3CompletedTreatmentDiabetic Nephropathies / Kidney Diseases / Proteinuria / Type 2 Diabetes Mellitus1
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHigh Blood Pressure (Hypertension)16
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Disorders1
3CompletedTreatmentHyperlipidemias / Hypertension,Essential1
3CompletedTreatmentHypertension,Essential2
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentMarfan Syndrome2
3CompletedTreatmentNonalcoholic Steatohepatitis1
3CompletedTreatmentProteinuria1
3CompletedTreatmentPulmonary Hypertension (PH)1
3Not Yet RecruitingTreatmentGlomerulonephritis, Immunoglobulin A (IgA)1
3Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3RecruitingTreatmentCerebral Small Vessels Disease1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3RecruitingTreatmentIgA Glomerulonephritis1
3RecruitingTreatmentMarfan Syndrome1
3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
3TerminatedTreatmentKidney Diseases / Renal Dysfunction / Type 2 Diabetes Mellitus1
3TerminatedTreatmentMarfan Syndrome1
3Unknown StatusPreventionMarfan Syndrome1
3Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
3Unknown StatusTreatmentMarfan Syndrome1
3Unknown StatusTreatmentProteinuria1
3Unknown StatusTreatmentSevere Sepsis1
3WithdrawnPreventionHyperoxaluria1
3WithdrawnTreatmentEssential Arterial Hypertension2
4Active Not RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4CompletedNot AvailableBMI >30 kg/m2 / High Blood Pressure (Hypertension) / Hyperglycemias1
4CompletedBasic ScienceRejection, Transplant1
4CompletedDiagnosticHyperaldosteronism1
4CompletedPreventionDiabetic Nephropathies1
4CompletedPreventionKidney Diseases / Proteinuria1
4CompletedPreventionRenal Stones1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis, Liver1
4CompletedTreatmentCongestive Heart Failure (CHF) / Low Cardiac Output1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetic Nephropathies / High Blood Pressure (Hypertension)1
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHigh Blood Pressure (Hypertension)8
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hypertension,Essential1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Impaired Glucose Tolerance (IGT)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricle Hypertrophy1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Pharmacogenetics1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Sleep Apnea Syndrome1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Strokes1
4CompletedTreatmentInfection, Human Immunodeficiency Virus I1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentLiver Transplant Recipients1
4CompletedTreatmentMacroalbuminuric Diabetic Nephropathy1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStroke, Ischemic1
4RecruitingBasic ScienceArterial hypoxia / Chemoreceptor Apnea / Respiration; Sleep Disorder / Sleep Disordered Breathing (SDB)1
4RecruitingPreventionBlood Pressures / High Blood Pressure (Hypertension) / Strokes1
4RecruitingTreatmentArterial Hypertension1
4RecruitingTreatmentBipolar Disorder (BD) / Cardiovascular Disease (CVD) / Major Depressive Disorder (MDD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Serious Mental Illness1
4RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4RecruitingTreatmentEmphysema1
4RecruitingTreatmentGlomerulonephritis / Proteinuria1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4RecruitingTreatmentIgA Nephropathy1
4RecruitingTreatmentPediatric Hypertension1
4SuspendedTreatmentEnd Stage Renal Disease (ESRD) / High Blood Pressure (Hypertension) / Proteinuria1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4Unknown StatusPreventionAlcoholic Liver Cirrhosis / Ascites1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema / Smoking1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)3
4Unknown StatusTreatmentHypertension, Resistant to Conventional Therapy / Hypertension,Essential1
4Unknown StatusTreatmentHypertension,Essential1
4WithdrawnTreatmentHeart Failure, Unspecified1
Not AvailableCompletedNot AvailableAging / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHealthy Normotensive Participants1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)2
Not AvailableCompletedNot AvailableHypertrophic Cardiomyopathy / Left Ventricular Hypertrophy / Myocardial Ischemia1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceInsulin Resistance / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceMemory, Long-Term / Memory, Short-Term1
Not AvailableCompletedDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableCompletedPreventionLeft Ventricular Hypertrophy / Renal Failure1
Not AvailableCompletedTreatmentAlbuminuria1
Not AvailableCompletedTreatmentAngiotensin II Type 1 Receptor Blockers / Diabetic Nephropathies / Glucose Metabolism / Obese / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Impaired Glucose Tolerance (IGT) / Insulin Resistance / Pre-Diabetic1
Not AvailableCompletedTreatmentDiabetic Nephropathies1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Proteinuria1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Type 2 Diabetes Mellitus2
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)6
Not AvailableCompletedTreatmentMicroalbuminuria1
Not AvailableCompletedTreatmentPrecancerous Conditions1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingBasic ScienceChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingBasic ScienceHealthy Volunteers1
Not AvailableRecruitingPreventionAtherosclerosis / Nephritis, Lupus1
Not AvailableRecruitingTreatmentIgA Nephropathy1
Not AvailableRecruitingTreatmentPosttraumatic Stress Disorders1
Not AvailableTerminatedScreeningCytochrome P450 Phenotype and Genotype Metrics1
Not AvailableTerminatedTreatmentACE Inhibitor / Angiotensin II Type 1 Receptor Blockers / Dose-Response Relationship, Drug / Progression, Disease / Proteinuria / Renal Insufficiency,Chronic1
Not AvailableTerminatedTreatmentRenal Insufficiency,Chronic1
Not AvailableUnknown StatusNot AvailableAtherosclerosis / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusNot AvailableHigh Blood Pressure (Hypertension)2
Not AvailableUnknown StatusTreatmentAngiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Kidney Insufficiency, Chronic / Proteinuria1
Not AvailableUnknown StatusTreatmentBicuspid Aortic Valve (BAV) / Thoracic Aortic Aneurysm (TAA)1
Not AvailableUnknown StatusTreatmentChronic Renal Diseases1
Not AvailableUnknown StatusTreatmentIgA Glomerulonephritis1
Not AvailableUnknown StatusTreatmentNonvalvular Atrial Fibrillation1
Not AvailableWithdrawnSupportive CareDyspnea / Lung Cancers / Pulmonary Complications / Radiation Fibrosis1

Pharmacoeconomics

Manufacturers
  • Merck research laboratories div merck co inc
  • Teva pharmaceuticals usa inc
  • Merck & Co., Inc.
Packagers
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Cardinal Health
  • Dispensing Solutions
  • Ipca Laboratories Ltd.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Merck & Co.
  • Mylan
  • Neuman Distributors Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral100.0 mg
TabletOral25.0 mg
TabletOral50.0 mg
TabletOral100 mg
TabletOral25 mg/1
TabletOral25 mg
TabletOral50 mg
TabletOral100 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
TabletOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Losartan Potassium 90 50 mg tablet Bottle211.78USD bottle
Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle78.05USD bottle
Hyzaar 100-25 mg tablet3.91USD tablet
Hyzaar 100-12.5 mg tablet3.87USD tablet
Hyzaar 100-12.5 tablet3.61USD tablet
Hyzaar 100-25 tablet3.61USD tablet
Losartan Potassium-HCTZ 100-12.5 mg tablet3.54USD tablet
Losartan Potassium-HCTZ 100-25 mg tablet3.54USD tablet
Cozaar 100 mg tablet3.41USD tablet
Losartan potassium 100 mg tablet3.14USD tablet
Hyzaar 50-12.5 mg tablet2.97USD tablet
Hyzaar 50-12.5 tablet2.65USD tablet
Cozaar 50 mg tablet2.5USD tablet
Losartan potassium 50 mg tablet2.26USD tablet
Cozaar 25 mg tablet1.92USD tablet
Losartan potassium 25 mg tablet1.72USD tablet
Cozaar 100 mg Tablet1.31USD tablet
Cozaar 25 mg Tablet1.31USD tablet
Cozaar 50 mg Tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5210079No1993-11-112010-11-11Us
US5608075No1992-03-042009-03-04Us
CA2085584No2003-02-112011-06-07Canada
CA1334092No1995-01-242012-01-24Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)184 °CPhysProp
water solubility0.82 mg/LNot Available
logP6.1Not Available
pKa5.5MERCK INDEX (1996); approx.
Predicted Properties
PropertyValueSource
Water Solubility0.0047 mg/mLALOGPS
logP4.5ALOGPS
logP5.08ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.85 m3·mol-1ChemAxon
Polarizability44.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.7812
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6993
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.5309
Renal organic cation transporterNon-inhibitor0.5689
CYP450 2C9 substrateNon-substrate0.6839
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateInhibitor0.5514
CYP450 2C9 inhibitorNon-inhibitor0.5423
CYP450 2D6 inhibitorNon-inhibitor0.8102
CYP450 2C19 inhibitorInhibitor0.6288
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.5382
CarcinogenicityNon-carcinogens0.6595
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6055 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5781
hERG inhibition (predictor II)Inhibitor0.8084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0000900000-657db16bb4bfe9184114
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-056r-0900000000-43bb8508cd1dbc71bcee
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-55368087829d113fdb7b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-af470646c547613f82a0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-746dcf7a43a3f8839c1d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-0bee80f7ccbc4b68eee0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-d845ae166a10faff242a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-2900000000-d39a309c02e1aaa956b0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-7900000000-d27d10ab008deb157e7a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0900700000-fef78a7f52d4aa515bb4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0900600000-c62f0db44e17f79e0c70
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0034900000-22ba49ec64d374c8965e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0191000000-8ff1b5a21f6ef4a462cd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0590000000-9841ff7f881c3e9c11b9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-0960000000-a24e287a018dae01dd0d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a5c-0930000000-ff3e675bd445225bf04e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pxu-0920000000-9adf4aef59fc1545fea6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0v00-1900000000-3591888cf5831cbe3d11
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0wmi-2900000000-ab9304c8cebc201d0178
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0j70-5900000000-efa87b7770206ac0ff3e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0491300000-f4b08850a154cfc2117c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0591300000-32a922edf20b3eb76950

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / 1,2,4,5-tetrasubstituted imidazoles / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides
show 2 more
Substituents
Biphenyl / Phenyltetrazole / 1,2,4,5-tetrasubstituted imidazole / Aryl chloride / Aryl halide / N-substituted imidazole / Azole / Heteroaromatic compound / Imidazole / Tetrazole
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, biphenylyltetrazole (CHEBI:6541)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004 Mar-Apr;55(2):195-203. [PubMed:15026875]
  3. Dickstein K, Timmermans P, Segal R: Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. 1998 Nov;7(11):1897-914. [PubMed:15991937]
  4. Anand-Srivastava MB, Palaparti A: Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J Physiol Pharmacol. 2003 Feb;81(2):150-8. [PubMed:12710529]
  5. Rocha I, Bras-Rosario L, Amparo-Barros M, Silva-Carvalho L: Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol. 2003 May;88(3):309-14. [PubMed:12719755]
  6. Guan J, Cheng DY, Chen XJ, Zhang Y, Wang H, Su QL: [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):774-7. [PubMed:15573751]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. [PubMed:11823761]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase c binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A10
Uniprot ID
Q9HAW8
Uniprot Name
UDP-glucuronosyltransferase 1-10
Molecular Weight
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbe...
Gene Name
UGT2B17
Uniprot ID
O75795
Uniprot Name
UDP-glucuronosyltransferase 2B17
Molecular Weight
61094.915 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  2. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  3. Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43. [PubMed:10725273]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Urate transmembrane transporter activity
Specific Function
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name
SLC22A12
Uniprot ID
Q96S37
Uniprot Name
Solute carrier family 22 member 12
Molecular Weight
59629.57 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sugar:proton symporter activity
Specific Function
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name
SLC2A9
Uniprot ID
Q9NRM0
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 9
Molecular Weight
58701.205 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:43